Daily Roundup

BVS.ASX MSB.ASX RFF.ASX ELV.ASX CTD.ASX

Bravura Solutions Lifts Earnings Outlook

Software company Bravura Solutions is expecting a stronger finish to the financial year than previously anticipated. The company has bumped up its cash EBITDA guidance to around $77 million, well ahead of the prior range of $69 million to $73 million. Revenue is expected to land within the $280 million to $285 million range as originally guided. The upgrade reflects robust demand for project services and disciplined cost management over the past six months, with CEO Colin Greenhill pointing to increased project work and stronger renewals driving the improved performance.

Mesoblast's Ryoncil Exceeds Revenue Expectations

Over in the biotech space, Mesoblast is celebrating strong early traction with its flagship product Ryoncil. The cell therapy generated $36 million in net revenue during the fourth quarter and $115 million for the full year ending June 30, 2026—comfortably surpassing initial projections. The company's CEO, Dr. Silviu Itescu, is optimistic about momentum building across major U.S. pediatric centers and expects the revenue growth trajectory to continue into the next fiscal year. With a solid capital position and a new five-year facility in place, Mesoblast is well-positioned to pursue label extensions and develop blockbuster products.

Rural Funds Group Offloads Assets to Trim Debt

Rural Funds Group has sold five assets for $255.6 million, securing an impressive average premium of 22.7% to their book values as of December 2025. The proceeds will be deployed to reduce the group's gearing to 31.6% from 39.1%, bringing it comfortably within the target range of 30 to 35 percent. The move also clears the way for an increase to the guarantee provided to J&F Australia from $160 million to $200 million. Settlements are expected to occur predominantly in the first half of 2027 and should provide a net benefit to distributions. The company is reaffirming its full-year AFFO forecast of 11.7 cents per unit.

Elevra Lithium Ramps Up Production

Elevra Lithium's North American Lithium operation in Québec delivered a solid quarter, producing approximately 54,479 dry metric tonnes of spodumene concentrate—a 15% jump from the prior quarter and the second-highest output on record. Sales volumes came in at roughly 33,977 dmt, with an average realised price of $919 per dmt. The lower pricing reflects contractual lagged mechanisms tied to older market prices, but the company expects future realised pricing to track more closely with current spot market levels as these legacy contracts roll off.

ASX Issues Compliance Warning

The ASX has flagged several entities that have been suspended for more than three months, setting specific deadlines for each to lodge outstanding periodic reports. Those that fail to meet their respective deadlines face removal from the official list. Reinstatement won't be automatic and will require ASX's approval of the entity's compliance record and trading resumption plans.